N/A
N=58
Assessment of Speckle Tracking Strain Predictive Value for Myocardial Fibrosis in Chagas Disease
Chagas Disease
Bottom Line
View on ClinicalTrials.gov: NCT02327052 ↗Enrolled (actual)
58
Serious AEs
—
Results posted
Mar 2021
Primary outcome: Primary: Correlation Between Longitudinal Global Strain and the Percentage of Myocardial Fibrosis on Magnetic Resonance — 16.8 percentage of fibrosis
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- No intervention was performed. (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Hospital Sao Rafael
- Primary completion
- Dec 2013
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Correlation Between Longitudinal Global Strain and the Percentage of Myocardial Fibrosis on Magnetic Resonance |
16.8 | — |
Summary
One of the most challenging issues of chronic Chagas disease is to provide earlier detection of heart involvement. Two-dimensional speckle tracking (2-D ST) echocardiography, a new imaging modality with useful applications in several cardiac diseases, has been validated for subjects with myocardial infarction against cardiac magnetic resonance (CMR). Here the investigators hypothesize that the longitudinal global strain (LGS) has an incremental value to ejection fraction for predicting myocardial fibrosis in subjects with Chagas disease.
Eligibility Criteria
Inclusion Criteria
- Chagas disease, established based on microbiological confirmation by two positive serologic tests (indirect hemagglutination and indirect immunofluorescence)
- Between 18 and 70 years of age.
Exclusion Criteria
- Previous myocardial infarction or history of coronary artery disease
- Primary valve disease
- Dialysis treatment of terminal renal failure
- Liver disease in activity
- Hematologic, neoplastic or bone diseases
- And MRI contraindications.
Data sourced from ClinicalTrials.gov (NCT02327052). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.